Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN3 | Q9H6Z9 | 6/20 | 0.69 |
| ▸ | EGLN1 | Q9GZT9 | 10/20 | 0.64 |
| ▸ | EGLN2 | Q96KS0 | 4/20 | 0.64 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8244838 | 0.93 | EGLN3 (0.78) | EGLN3EGLN1EGLN2CYSLTR2MEN1 | |
| SCHEMBL8247226 | 0.88 | EGLN3 (0.85) | EGLN3EGLN1EGLN2MEN1KMT2A | |
| SCHEMBL5311749 | 0.88 | EGLN3 (0.72) | EGLN3EGLN1EGLN2MEN1KMT2A | |
| SCHEMBL5309011 | 0.84 | EGLN1 (0.73) | EGLN3EGLN1EGLN2CYSLTR2HIF1A | |
| SCHEMBL8238784 | 0.83 | EGLN3 (0.67) | EGLN3EGLN1EGLN2MEN1KMT2A | |
| SCHEMBL8248296 | 0.82 | EGLN3 (1.00) | EGLN3EGLN1EGLN2MEN1KMT2A | |
| SCHEMBL8244813 | 0.82 | EGLN1 (0.57) | EGLN3EGLN1EGLN2CYSLTR2HIF1A | |
| SCHEMBL8248494 | 0.81 | EGLN1 (0.75) | EGLN3EGLN1EGLN2CYSLTR2HIF1A | |
| SCHEMBL8247380 | 0.81 | EGLN3 (0.74) | EGLN3EGLN1EGLN2HIF1A | |
| SCHEMBL8247316 | 0.81 | EGLN3 (0.74) | EGLN3EGLN1EGLN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007038571-A2 | PROLYL HYDROXYLASE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-04-05 | — | — | WO | disclosed |